Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLChristin Schütz, Andreas Burchert, Jolanta Dengler et al.|Leukemia|2017Cited by 106
A Gain-Of-Function Mutation in the Plcg2 Gene Protects Mice from Helicobacter felis-Induced Gastric MALT LymphomaJennifer Goßmann, Minh Q. Huynh, Manfred Stolte et al.|PLoS ONE|2016Cited by 11
Frequency of CTLA-4 Receptor Ligand (CD86, B7.2) -Positive Plasmacytoid Dendritic Cells Predicts Risk of Disease Recurrence after Tyrosine-Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Results from a Prospective Substudy of the Euroski TrialAndreas Burchert, Christin Schütz, Sabrina Inselmann et al.|Blood|2015Cited by 9
The Inverse Agonist DG172 Triggers a PPARβ/δ-Independent Myeloid Lineage Shift and Promotes GM-CSF/IL-4-Induced Dendritic Cell DifferentiationSonja Lieber, Rolf Müller, Frithjof Scheer et al.|Molecular Pharmacology|2014Cited by 8
Expression of the CTLA-4 ligand CD86 (B7.2) on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in chronic myeloid leukemiaAndreas Burchert, Christin Schütz, Sabrina Inselmann et al.|RWTH Publications (RWTH Aachen)|2016Cited by 0